Management of childhood malignant peripheral nerve sheath tumor

Pediatric Drugs

Volumn 9, Issue 4, 2007, Pages 239-248

  Ferrari, Andrea ^a   Bisogno, Gianni ^b   Carli, Modesto ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PLATINUM DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG SENSITIVITY; GENE MUTATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INCIDENCE; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; PERIPHERAL NERVE TUMOR; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; SURGICAL APPROACH; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DRUG DELIVERY SYSTEMS; HUMANS; INFANT; INFANT, NEWBORN; NEOPLASM STAGING; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; PROGNOSIS; TREATMENT OUTCOME;

EID: 34548081445     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200709040-00005     Document Type: Review

References (59)

1. Miser JS, Pappo AS, Triche TJ, et al. Other soft tissue sarcomas of childhood. In: Pizzo PA, Poplack DC, editors. Principles and practice of pediatric oncology. 4th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 1017-50
2. Enzinger FM, Weiss SW. Malignant tumor of the peripheral nerves. In: Enzinger FM, Weiss SW, editors. Soft tissue tumors. 4th ed. St Louis (MO): CV Mosby, 2001: 1209-63
3. Ferrari A, Casanova M. New concepts for the treatment of pediatric non-rhabdo-myosarcoma soft tissue sarcomas. Expert Rev Anticancer Ther 2005; 5 (2): 307-18
4. Carli M, Ferrari A, Mattke A, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German Soft Tissue Sarcoma Cooperative Group. J Clin Oncol 2005; 23: 8422-30
5. Sorensen SA, Mulvihill JJ, Nielsen A. Long-term follow up of von Recklinghausen neurofibromatosis. N Engl J Med 1986; 314: 1010-5
6. Parham DM, Webber BL, Jenkins JJ, et al. Nonrhabdomyosarcomatous soft tissue sarcomas of childhood: formulation of a simplified system for grading. Mod Pathol 1995; 8: 705-10
7. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adults patients with soft tissue sarcoma. J Clin Oncol 1997; 15: 350-62
8. Ferner RE, Lucas JD, O'Doherty MJ, et al. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry 2000; 68 (3): 353-7
9. Harmer MH. TNM classification of pediatric tumors. Geneva: UICC International Union Against Cancer, 1982: 23-8
10. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study I: a final report. Cancer 1988; 61: 209-20
11. Ward BA, Gutmann DH. Neurofibromatosis 1: from lab bench to clinic. Pediatr Neurol 2005; 32 (4): 221-8
12. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997; 278 (1): 51-7
13. Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet 1997; 70: 138-43
14. Friedman JM. Neurofibromatosis 1: clinical manifestations and diagnostic criteria. J Child Neurol 2002; 17 (8): 548-54
15. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990; 249: 181-6
16. Xu GF, O'Connell P, Viskochil D. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990; 62: 599-608
17. Wu R, Lopez-Correa C, Rutkowski JL, et al. Germline mutations in NF1 patients with malignancies. Genes Chromosomes Cancer 1999; 26: 376-80
18. Glover TW, Stein CK, Legius E, et al. Molecular and cytogenetic analysis of tumors in von Recklinghausen neurofibromatosis. Genes Chromosomes Cancer 1991; 3 (1): 62-70
19. Blatt J, Jaffe R, Deutsch M, et al. Neurofibromatosis and childhood tumors. Cancer 1986; 57 (6): 1225-9
20. Matsui I, Tanimura M, Kobayashi N, et al. Neurofibromatosis type 1 and childhood cancer. Cancer 1993; 72: 2746-54
21. Shearer P, Parham D, Kovnar E, et al. Neurofibromatosis type I and malignancy: review of 32 pediatric cases treated at a single institution. Med Pediatr Oncol 1994; 22 (2): 78-83
22. Sordillo PP, Helson L, Hajdu SI, et al. Malignant schwannoma: clinical characteristics, survival, and response to therapy. Cancer 1981; 47: 2503-9
23. Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumours: a clinicopathological study of 120 cases. Cancer 1986; 57: 2006-21
24. Raney B, Schnaufer L, Ziegler M, et al. Treatment of children with neurogenic sarcoma: experience at the Children's Hospital of Philadelphia, 1958-1984. Cancer 1987; 59: 1-5
25. Hruban RH, Shiu MH, Senie RT, et al. Malignant peripheral nerve sheath tumours of the buttock and lower extremity: a study of 43 cases. Cancer 1990; 66: 1253-65
26. Meis JM, Enzinger FM, Martz KL, et al. Malignant peripheral nerve sheath tumors in children. Am J Surg Pathol 1992; 16: 694-707
27. Wanebo JE, Malik JM, Van den Berg SR, et al. Malignant peripheral nerve sheath tumours: a clinicopathologic study of 28 cases. Cancer 1993; 71: 1247-53
28. Doorn PF, Molenaar WM, Buter J, et al. Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis. Eur J Surg Oncol 1995; 21: 78-82
29. DeCou JM, Rao BN, Parham DM, et al. Malignant peripheral nerve sheath tumors: the St. Jude Children's Research Hospital experience. Ann Surg Oncol 1995; 2: 524-9
30. Wong WW, Hirose T, Scheithauer BW, et al. Malignant peripheral nerve sheath tumour: analysis of treatment outcome. Int J Rad Oncol Biol Phys 1998; 42 (2): 351-60
31. Casanova M, Ferrari A, Spreafico F, et al. Malignant peripheral nerve sheath tumors in children: a single-institution twenty-year experience. J Pediatr Hematol Oncol 1999; 21: 509-13
32. Cashen DV, Parisien RC, Raskin K, et al. Survival data for patients with malignant schwannoma. Clin Orthop Rel Res 2004; 426: 69-73
33. Anghileri M, Miceli R, Fiore M, et al. Malignant peripheral nerve sheath tumours: prognostic factors and survival in a series of patients treated at a single institution. Cancer 2006; 107 (5): 1065-74
34. D'Agostino AN, Soule EH, Miller RH. Sarcomas of the peripheral nerves and somatic soft tissue associated with multiple neurofibromatosis (von Reck-linghausen's disease). Cancer 1963; 16: 1015-27
35. Evans DGR, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002; 39: 311-4
36. Birindelli A, Perrone F, Oggionni M, et al. Pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumours. Lab Invest 2001; 81: 833-44
37. De Raedt T, Brems H, Wolkenstein P, et al. Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet 2003; 72: 1288-92
38. Rubin JB, Gutmann DH. Neurofibromatosis type 1: a model for nervous system tumour formation? Nat Rev Cancer 2005; 5 (7): 557-64
39. Upadhyaya M, Shaw DJ, Harper PS. Molecular basis of neurofibromatosis type 1 (NF1): mutation analysis and polymorphisms in the NF1 gene. Human Mutat 1994; 4: 83-101
40. Basu TN, Gutmann DH, Fletcher JA, et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992; 356: 713-5
41. Perrone F, Tabano S, Colombo F, et al. p15INK4b, p14ARF and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumours. Clin Cancer Res 2003; 9: 4132-8
42. Legius E, Dierick H, Wu R, et al. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer 1994; 10 (4): 250-5
43. Ghosh BC, Ghosh L, Huvos AG, et al. Malignant schwannoma: a clinicopathologic study. Cancer 1973; 31: 184-90
44. Ferrari A, Bisogno G, Macaluso A, et al. Soft tissue sarcomas in children and adolescents with neurofibromatosis type 1. Cancer 2007; 109 (7): 1406-12
45. Ferrari A, Casanova M, Collini P, et al. Adult-type soft tissue sarcomas in pediatric age: experience at the Istituto Nazionale Tumori in Milan. J Clin Oncol 2005; 23: 4021-30
46. Pratt CB, Pappo AS, Gieser P, et al. Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol 1999; 17: 1219-26
47. Pratt CB, Maurer HM, Gieser P, et al. Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group Study. Med Pediatr Oncol 1998; 30: 201-9
48. Spunt SL, Poquette CA, Hurt YS, et al. Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children's Research Hospital. J Clin Oncol 1999; 17: 3697-705
49. Spunt SL, Ashley Hill D, Motosue AM, et al. Clinical features and outcome of initially unresected nonmetastatic pediatric nonrhaddomyosarcoma soft tissue sarcoma. J Clin Oncol 2002; 20: 3225-35
50. Pappo AS, Devidas M, Jenkins J, et al. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol 2005; 23 (18): 4031-8
51. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997; 350: 1647-54
52. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001; 19: 1238-47
53. Ferrari A, Brecht IB, Koscielniak E, et al. The role of adjuvant chemotherapy in surgically-resected adult-type soft tissue sarcomas of children and adolescents. Ped Blood Cancer 2005; 45: 128-34
54. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998; 16: 197-203
55. O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft tissue sarcoma of the limbs: a randomized trial. Lancet 2002; 359: 2235-41
56. DeClue JE, Heffelfinger S, Benevento G, et al. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest 2000; 105 (9): 1233-41
57. Ling BC, Wu J, Miller SJ, et al. Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell 2005; 7 (1): 65-75
58. Albritton KH, Rankin C, Coffin C, et al. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST) [abstract no. 9518]. Proc Am Soc Clin Oncol 2006; 24: 18S
59. Widemann BC, Salzer WL, Arceci RJ, et al. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 2006; 24 (3): 507-16